Lebrikizumab: a New Anti-Il-13 Agent for Treating Moderate-to-severe Atopic Dermatitis.
EXPERT OPINION ON BIOLOGICAL THERAPY（2025）
Key words
Atopic dermatitis,biologics,efficacy,interleukin-13,lebrikizumab,patient profile,safety
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined